The first-line drugs for tuberculosis (TB) consist of a combination of medications: isoniazid, a rifamycin (typically rifampin, but sometimes rifapentine or rifabutin), pyrazinamide, and ethambutol. Additionally, moxifloxacin is considered a first-line agent when used in combination with isoniazid, rifapentine, and pyrazinamide.
Therefore, there is no single "first-line drug" for TB. Treatment always involves a combination of these medications.
Here's a breakdown of why this combination therapy is crucial:
-
Multiple drugs target different aspects of the bacteria: TB bacteria can become resistant to single drugs quickly. Using multiple medications simultaneously attacks the bacteria in different ways, reducing the chance of resistance developing.
-
Intensive phase and continuation phase: TB treatment usually involves two phases. The initial "intensive phase" uses all or most of the first-line drugs to rapidly reduce the bacterial load. The "continuation phase" uses fewer drugs to eliminate any remaining bacteria and prevent relapse.
-
Individualized treatment: While the core drugs remain the same, doctors may adjust the specific regimen based on factors like the patient's overall health, drug sensitivities, and the severity of the TB infection.
In summary, the first-line treatment for TB is a multi-drug regimen that includes isoniazid, a rifamycin (rifampin, rifapentine, or rifabutin), pyrazinamide, and ethambutol, with moxifloxacin sometimes included.
